Tempest Therapeutics (TPST) announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the U.S. Food and Drug Administration, FDA, to evaluate TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin, PGE2, signaling, in a Phase 2 clinical trial for the treatment of patients with Familial Adenomatous Polyposis, FAP.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPST: